Rocket Pharmaceuticals Stock Quote RCKT - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

2.93

Bid

2.95

Ask

2.97

Volume

3,108,155

2.92 Day's Range 3.08

2.19 52 Week Range 26.98

Market Cap

315.672M

Previous Close

3.07

Open

2.96

Last Trade

484

2.93

(formt)

Last Trade Time

Financial Volume

$ 9,275,854

VWAP

2.9844

Average Volume (3m)

5,066,474

Shares Outstanding

107,737,919

Dividend Yield

PE Ratio

-0.02

Earnings Per Share (EPS)

-2.4

Revenue

Net Profit

-258.75M

Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesio... Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.rocketpharma.com

Headquarters

Wilmington, Delaware, USA

Founded

Rocket Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RCKT. The last closing price for Rocket Pharmaceuticals was $3.07. Over the last year, Rocket Pharmaceuticals shares have traded in a share price range of $ 2.19 to $ 26.98.

Rocket Pharmaceuticals currently has 107,737,919 shares outstanding. The market capitalization of Rocket Pharmaceuticals is $330.76 million. Rocket Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.02.

Rocket Pharmaceuticals Shares Plunge After Patient Death Leads to Trial Suspension

Rocket Pharmaceuticals (NASDAQ:RCKT) saw its stock tumble 57% in premarket trading after reporting a patient death linked to serious adverse...

Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease

Conference call to be held later today at 8:30 a.m. ET Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology...

Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy

RP-A601 was generally well-tolerated at a dose of 8.0E13 GC/kg with no dose-limiting toxicities in all three patients with up to 12 months...

Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.12	4.27046263345	2.81	3.3354	2.81	4393552	3.0652907	CS
4	-3.94	-57.3508005822	6.87	6.885	2.19	8160278	2.95119125	CS
12	-5.335	-64.5493042952	8.265	8.8	2.19	5066474	4.60664775	CS
26	-9.39	-76.2175324675	12.32	13.35	2.19	3187060	6.03951774	CS
52	-19.77	-87.0925110132	22.7	26.98	2.19	2031206	8.91055155	CS
156	-8.21	-73.6983842011	11.14	32.525	2.19	1256165	14.24100183	CS
260	-14.78	-83.45567476	17.71	67.48	2.19	947291	18.01920082	CS

RCKT - Frequently Asked Questions (FAQ)

What is the current Rocket Pharmaceuticals share price?

The current share price of Rocket Pharmaceuticals is $ 2.93

How many Rocket Pharmaceuticals shares are in issue?

Rocket Pharmaceuticals has 107,737,919 shares in issue

What is the market cap of Rocket Pharmaceuticals?

The market capitalisation of Rocket Pharmaceuticals is USD 330.76M

What is the 1 year trading range for Rocket Pharmaceuticals share price?

Rocket Pharmaceuticals has traded in the range of $ 2.19 to $ 26.98 during the past year

What is the PE ratio of Rocket Pharmaceuticals?

The price to earnings ratio of Rocket Pharmaceuticals is -0.02

What is the reporting currency for Rocket Pharmaceuticals?

Rocket Pharmaceuticals reports financial results in USD

What is the latest annual profit for Rocket Pharmaceuticals?

The latest annual profit of Rocket Pharmaceuticals is USD -258.75M

What is the registered address of Rocket Pharmaceuticals?

The registered address for Rocket Pharmaceuticals is 300 DELAWARE AVENUE, SUITE 270, WILMINGTON, DELAWARE, 19801

What is the Rocket Pharmaceuticals website address?

The website address for Rocket Pharmaceuticals is www.rocketpharma.com

Which industry sector does Rocket Pharmaceuticals operate in?

Rocket Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
RBNERobin Energy Ltd	$ 13.85 (313.43%)	101.81M
OPOceanPal Inc	$ 1.63 (125.45%)	80.28M
LGHLWLion Group Holding Ltd	$ 0.0052 (116.67%)	6.87M
NEONNeonode Inc	$ 16.83 (68.47%)	4.78M
ICONIcon Energy Corporation	$ 2.90 (62.01%)	59.04M
SBETSharpLink Gaming Inc	$ 9.2275 (-71.63%)	41.92M
AIHSSenmiao Technology Ltd	$ 0.381 (-63.01%)	16.8M
CHSNChanson International Holding	$ 0.22 (-60.00%)	15.15M
KWMK Wave Media Ltd	$ 2.91 (-50.43%)	2.59M
JZXNJiuzi Holdings Inc	$ 1.56 (-46.39%)	2.24M
HCTIHealthcare Triangle Inc	$ 0.0201 (-33.00%)	856.89M
GNLNGreenlane Holdings Inc	$ 0.0101 (-34.42%)	792.34M
CGBSCrown LNG Holdings Ltd	$ 0.1104 (31.43%)	788.42M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	$ 12.655 (3.81%)	246.13M
NVDANVIDIA Corporation	$ 141.97 (-2.09%)	180.81M

glenn1919 2 weeks ago

RCKT...........................................https://stockcharts.com/h-sc/ui?s=RCKT&p=W&b=5&g=0&id=p86431144783

👍️0

DeafTrader2 3 weeks ago

Regardless of what have happened to this incident, i am betting the farm on this company.

👍️0

glenn1919 2 months ago

RCKT..........................................https://stockcharts.com/h-sc/ui?s=RCKT&p=W&b=5&g=0&id=p86431144783

👍️0

glenn1919 2 months ago

RCKT..................................https://stockcharts.com/h-sc/ui?s=RCKT&p=W&b=5&g=0&id=p86431144783

👍️0

Monksdream 4 months ago

RCKT 10Q due MONDAY 2/24

👍️0

Monksdream 1 year ago

RCKT new 52 week high

👍️0

make it happen 2 years ago

How's it up 38% @ $21.00 PPS when diluting $175,000,000 million @ $16.00??

👍️0

trkyhntr 4 years ago

I have been away at hunting camp for a few weeks, and when I got back I was pleasantly surprised. This puppy has doubled! Any thoughts as to how much more upside there is?

👍️0

ClayTrader 5 years ago

* * $RCKT Video Chart 12-09-2020 * *

Link to Video - click here to watch the technical chart video

👍️0

Glider549 5 years ago

Check out Seeking Alpha, January 27, article.
Lots of insider buying and Fast Track status.

👍️0

RUSTYJ 6 years ago

How you figure a lot power , Gravity takes it down

👍️0

investor86 7 years ago

This got a lot of power!!

👍️0

trkyhntr 7 years ago

This is a new board for this stock. Rocket Pharmaceuticals, Inc., formerly Inotek Pharmaceuticals Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye's natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye's trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.

👍️0

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Rocket Pharmaceuticals Inc (RCKT) Quote

Rocket Pharmaceuticals Inc (RCKT)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

About Rocket Pharmaceuticals Inc

Ask ADVFN Intelligence (AI)

RCKT Latest News

Rocket Pharmaceuticals Shares Plunge After Patient Death Leads to Trial Suspension

Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease

Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy

Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy

Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

Rocket Pharmaceuticals Shares Plunge After Patient Death Leads to Trial Suspension

Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease

Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy

Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy

Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

RCKT - Frequently Asked Questions (FAQ)

Movers

RCKT Discussion

Your Recent History

Company

Business

Popular

Get The App

Sign in

Go Ad-Free